Rebeca Rocha, patent specialist at Bhering Advogados, contributed with comments to Valor Econômico Newspaper about the recent decision of the Brazilian Patent and Trademark Office (BRPTO), which revoked the patent on a drug based on cannabidiol diluted in corn oil, granted to a pharmaceutical from Paraná.

The decision was made by the presidency of the agency after analyzing requests from three applicants who alleged, among other aspects, the lack of inventiveness in the composition of the drug.

According to Rebeca, the annulment of the patent opens the way for other laboratories to produce medicines containing cannabidiol. It is a very important decision for the access of patients to medicines containing this substance, of interest for the treatment of diseases such as epilepsy, Parkinson’s, schizophrenia, anxiety and chronic pain relief. Rebeca also emphasizes that patents represent an essential instrument in favor of innovation. In this case, however, the patent did not meet the necessary requirements for its grant.

The full article can be read (in Portuguese) at: https://bit.ly/valor-cbd-RR-2021 (requires a subscription).

 

---